To evaluate the clinical effectiveness of sorafenib and sunitinib in metastatic renal cell carcinoma (RCC) by using indirect comparison meta-analysis. METHODS: Systematic literature search of Medline, Embase, Cochrane controlled trials register. All randomized clinical trials of sorafenib or sunitinib versus interferon alfa for treating metastatic renal-cell carcinoma were included. Study selection, data extraction and quality assessment were performed by two reviewers with disagreements being resolved by consensus. The effects of sorafenib and sunitinib on progression-free survival were compared indirectly using indirect treatment comparison program, with interferon alfa (IFN) as a common comparator. RESULTS: Two studies were included. Median progression-free survival was prolonged with the treatment of sunitinib (11 months) compared to interferon alfa (5 months). For the comparison of sorafenib and interferon-alfa, the median progression-free survival was similar (median PFS: 5.7 months vs. 5.6 months). Indirect comparison suggests that sunitinib is not superior to sorafenib for prolongation of progress free survival (hazard ratio 0.37; 95% CI: 0.236-0.58, P = 0.0189). CONCLUSIONS: There is no signifi cant evidence to suggest that treatment with sunitinib has clinical advantages over treatment with sorafenib in patients with metastatic RCC. To determine whether the association between the different dosage of hormone replacement therapy (HRT) and the incidence of breast cancer (BC) in postmenopausal women with HRT formulation. METHODS: Patients who had at least one outpatient visit for postmenopausal syndrome (ICD-9-CM code 627) with estrogen prescription in Taiwan National Health Insurance (NHI) claims database during 1999-2006 were identifi ed as the study cases. There were 883,052 women identifi ed from the dataset. The index date was defi ned as the date of the fi rst menopausal visit with estrogen prescription during the study period. To identify any BC events, each case was tracked from the index date until December 31, 2006 or death, whichever came fi rst. Women without events were censored on December 31, 2006. Survival analysis was performed to assess whether cumulative estrogen dosage and combined progesterone were independent risk factors of BC. RESULTS: A total of 5524 cases of BC were identifi ed during the study period. Women with higher dosage of estrogen had signifi cantly higher risk of BC than women with lower dosage (HR = 2.23; P < 0.0001). The risk of BC was even higher when progesterone was combined with estrogen (HR = 1.08; P = 0.036). Women aged 60-69 (HR = 0.87, P = 0.002) and >70 (HR = 0.66, P < 0.0001) had lower risk of BC, compared with women aged <60. Women living in the northern part of Taiwan and in areas with higher urbanization level had higher risk of BC, compared with their counterparts. CONCLUSIONS: Hormone replacement therapy in postmenopausal women seemed to be associated with an increased risk of BC. 10,609,682, 7,335,176, 5,927,478, 2,492,148, and 376,927, respectively. CONCLUSIONS: Cancer incidence rates vary by region and gender in China. The overall burden of cancer is heavy and more attention should be paid to cancer prevention and control.
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PCN8 IDENTIFYING KEY PROCEDURES IN HEPATOCELLULAR CARCINOMA PATIENTS WITH HIGHEST PAYER BUDGET IMPACT IN A COMMERCIALLY INSURED POPULATION IN THE UNITED STATES
Tsong W 1 , Singer ME 2 , Ray S 1 1 Abbott Laboratories, Abbott Park, IL, USA; 2 Case Western Reserve University School of Medicine, Cleveland, OH, USA OBJECTIVES: Although hepatocellular carcinoma (HCC) is a highly prevalent disease in East Asia with a growing incidence in the US, there is a limited understanding of health-care procedures and their economic impact. This study identifi es the procedures with the highest payer budget impact in a commercially insured US population. METHODS: The MEDSTAT insurance claims database (January 1, 2000-December 31, 2008) was used to identify a cohort of patients with > = 1 HCC claim (index = fi rst claim), age > = 18, and no other cancer diagnoses. For each procedure code, all payments (2009 USD) were summed across the cohort and divided by the total patientmonths to estimate the per patient-month (PM) cost. The PM costs were ranked to identify procedures with the highest payer budget impact. The proportion of patients utilizing each procedure was calculated to evaluate whether PM costs were driven by a minority of patients. RESULTS: The study sample included 2927 patients: mean age 50.4 years, 57% male, and median 9 months follow-up. The inpatient procedures with the highest budget impact were: liver transplant and/or intestinal transplant ($526/ PM, 4.6% of patients), tracheostomy with mechanical ventilation ($204/PM, 0.2%), disorders of liver except malignancy/cirrhosis/alcoholic hepatitis ($96/PM, 5.1%). For hospital outpatient procedures, they were: magnetic resonance imaging (MRI) of the abdomen ($18/PM, 15%), computed tomography of abdomen ($13/PM, 17%), and transcatheter occlusion/embolization ($8/PM, 4%). For offi ce outpatient procedures, they were: low complexity visits ($26/PM, 70%), moderate complexity visits ($18/ PM, 18%), and MRI of abdomen ($8/PM, 7%). Patients with > = 1 sorafenib prescription (<2% of cohort) had a minimal impact on the results. CONCLUSIONS: The key procedures with the highest budget impact appear to be related to both cancer and liver disease. These costs may be reduced with improved anticancer therapy which provides better cancer control and reduces the exacerbation of liver disease from tumor growth.
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